Neuro psychiatric illnesses are commonly recognised these days in the intensive care especially with the increasing aging population and more intensive care admissions. However they are still inadequately diagnosed and treated disease entities as a majority of these patients do not seek the help of specialists psychiatrists Of course the number of drugs used in psychiatry has explosively increased in recent years. As a corollary to this, the phenomenon of drug-drug interaction between psychiatric drugs and other drugs has come to the forefront. Drug-drug interaction (DDI)) is the response (pharmacological or clinical) of altered drug effects or increase in adverse effects when two or more drugs are used simultaneously 1,2 This effect may be different from the usual action of the individual drugs when used alone. Potential drug-drug interaction (PDDI) are those where theoretically there may be an interaction between the drugs but have not clinically occurred.
Prevalence and Factors Determining DDI in ICUs
The prevalence of drug interactions in ICU, in general, ranges from 45% to 85%. 1, 2 Determinants of drug interactions depend upon number of drugs (increase in incidence of interactions with increased number of drugs), age, type of drug, presence of organ damage or comorbidities. Incidence of PDDI increases by 10-20% in patients using 10-20 drugs. 6 In one study the average number of drugs used in an ICU patient was found to be seven 6, 7 and about 45% of the ICU prescriptions included some PDDI.
Drugs Commonly Involved in DDIs
In multispecialty ICUs, dexamethasone, frusemide , nifedipine and enoxaparin were identified to have highest frequency of PDDI in some studies. 7 In neurocritical care units anticonvulsants and psychiatric medications often are involved in DDIs. The most frequent interactions are between drugs acting on the cardiovascular system, corticosteroids, antibiotics, antidepressants, antipsychotics, immunosuppressants and opioids. 4 Nervous system medications account for 40% of DDI and midazolam and fentanyl were most frequently associated with DDI. 4 
Mechanism of DDIs
Pharmacokinetic types of DDI are common and involve the absorption, metabolism, distribution and elimination of drugs.
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EffEcts o f ddI
DDIs are often the commonest cause of adverse drug reactions leading to increase in organ damages, morbidity, ineffective therapy, increased length of hospital stay, expenses as well as poor long term outcome and mortality. 1, 2, 3, 4 The adverse reactions often affect the cardiovascular and nervous systems.
The Vulnerable Population
The elderly and the critically ill patients are more at risk of adverse events of DDIs as they are the groups where polypharmacy is common. The pharmacokinetics of the medications involved along with the compromised organ systems adds to the often higher doses and longer duration of drug administration in the intensive care unit (ICU). Most of the drugs used are parenteral formulations where the adjuvants added may increase the toxicity of the drugs. 4, 5, 6 Indian Journal of Critical Care Medicine, June 2019;23 (Suppl 2) Usually PDDIs are often between drugs metabolized by the same Cytochrome P450 (CYP 450) enzymes and/ or due to concomitant administration of drugs that are inducers or inhibitors of these enzyme systems. 1 Drugs metabolized by this route include drugs like midazolam, tacrolimus, cyclosporine and phenytoin. CYP450 inducers and inhibitors of clinical importance commonly used in ICU are amiodarone, fluconazole and carbamazepine (CBZ). Half of all drugs are metabolized by the CYP450 system and most DDIs involve the first -pass metabolim. Enzyme systems include CYPIA2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4. Of mention here is the P glycoprotein transporter system (P-gp) which is found in the gastrointestinal and central nervous system and which determines the transport of drugs across the blood brain barrier. Most drugs used in psychiatry use this system. Pharmacodynamic interaction may also be seen and involves the change in the mechanism of drug action. Genetic polymorphism may also alter drug action.
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clAssIfIcAtIon o f PddIs
It is advantageous to be aware of PDDIs. This helps clinicians to be cautious while prescribing drugs of different classes. Various softwares and databases have been developed to identify DDIs and PDDIs. 1, 4 Yet some may still be undiscovered. PDDIs are classified as: • Contraindicated for concurrent use.
• Major-Life threatening adverse events that may necessitate intervention and if these drugs are used the clinician needs to justify the usage of the same.
• Moderate-Most PDDIs fall in this category. These may exacerbate patients' illness and warrant alternate therapy.
• Minor-Usually do not produce adverse events but in the eventuality of one, needs change in the treatment strategy.
Psychiatric Illness and Critical Care
Patients with psychiatric diagnoses are common among severely ill patients and may represent a significant proportion of those treated in the ICUs. 8 Often patients on psychotropic medications admitted to the ICU may require dose reduction or discontinuation of these drugs and this may lead to severe complications and even acute psychosis. 9 Withdrawal after long term intake of baclofen has found to cause delirium, agitation and seizures. Withdrawal of benzodiazepines may precipitate seizures, agitation and hallucinations while that of SSRIs leads to flu-like illness. Many critically ill people suffering from COPD, diabetes or cardiovascular disorders suffer from mental illness and this leads to increased morbidity Chronic psychiatric medication or associated substance abuse could induce immunosuppression as suggested in several studies and could worsen organ dysfunction and increase risk of nosocomial infections in these population during ICU stay. 10 On the other hand 60-80% of critically ill patients especially on mechanical ventilation may suffer from pain, agitation, insomnia and delirium and are regularly given analgesics, sedatives and antipsychotics. These add to the morbidity due to DDIs and adverse reactions. 11 It is implied that a thorough history of prior health status including medication intake should be taken in all. About 3% of the patients requiring mechanical ventilation had one or more psychiatric illness in a Danish study. 12 Majority did not have any psychiatric illness or medication prior to hospitalization in ICU. Mood and anxiety disorders after a critical illness were common. The primary psychiatric disorders admitted to ICU include anxiety disorders, schizophrenia, depression, bipolar disorders, depression, substance abuse or dependence. 13 Self-harm including drug overdosages, hanging, drowning, corrosive ingestion, organophosphorus poisoning are common. 11 Hence patients with psychiatric disorders may be admitted with critical illness or critically ill patients may develop psychiatric disorders while in ICU.
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Use of Psychiatric Drugs in ICU
Benzodiazepines (BZD) , antidepressants and antipsychotics are often the first psychiatric medicines to be added in the critical care units. 13 BZD (midazolam and lorazepam have been used to manage agitation in the ICU for ages However the current recommendations suggest a non BZD agent for sedation in ICU. 13 The antipsychotics used include the first generation ones with high affinity for dopaminergic (D2) receptors while second generation agents are the serotonin receptor antagonists (5HT2), used in schizophrenia, agitation and delirium. Nowadays atypical antipsychotics like quetiapine, olanzapine and risperidone are being more frequently used due to less side effects. Haloperidol which is an age old drug for delirium may precipitate alarming extrapyramidal symptoms (EPS). 13 First generation antipsychotics like thioridazine and chlorpromazine which are useful in hyperactive delirium have more anticholinergic effects and may produce arrhythmias as well as EPS (D2 inhibition).To summarise, BZDs, neuroleptics, antipsychotics other than neuroleptics, lithium, selective serotonin reuptake inhibitors (SSRIs), serotonin -norepinephrine reuptake inhibitors (SNRIs), tri and tetra cyclic antidepressants (TCA) and monoamine oxidase inhibitors (MAOI) are commonly used in psychiatric patients.
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Adverse Effects of Psychiatric Drugs
Most DDIs exacerbate the known side affects of the interacting drugs. Hence it is important to be aware of the common adverse effects of psychiatric drugs before knowing the drugs implicated in interaction (Table 1) . [13] [14] [15] Below is a list of common pharmacokinetic and pharmacodynamics interactions of psychiatric drugs with others maily cardiovascular drugs (Tables 2 to 5) 13-16 .
Drug Interactions of Chronic Neuropsychiatric Drugs
Indian Journal of Critical Care Medicine, June 2019;23 (Suppl 2) Neurocritical care units often face the complex situations where patients with cardiac disorders co-exist with neurological and psychiatric diseases. As has been mentioned earlier DDIs with cardiac medications or cardiovascular adverse effects of drug combinations may precipitate life threatening situations in the ICU. Following is a list of some important DDIs between cardiovascular and psychotropic drugs. 16 The major DDIs are mentioned in Table 4 and the moderate ones in Table 5 .
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conclusIon
Neurocritical care units deal with unique and complex disease states involving often multiple organ systems and poly pharmacy is unavoidable. Psychotropic drug usage for primary psychiatric illness or for psychiatric symptoms developing after ICU admission is increasing Drug-drug interactions is a natural fall out in this situation. It is important to be prepared for such situations.
Softwares and databases containing these information are easily accessible. Documenting such adverse events should be a part of the hospital protocol. 
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